公开(公告)号：KR1020110089223A

公开(公告)日：2011-08-05

申请号：KR1020100008852

申请日：2010-01-30

Applicant: 원광대학교산학협력단

Inventor： 김윤철 ,  정길생 ,  박현 ,  김은철 ,  이동성 ,  리빈

IPC: A61K31/05 ,  A61K36/906 ,  A61P25/28 ,  A61P25/00

Abstract: PURPOSE: A pharmaceutical composition and neutraceutical food containing standardized fraction of crude ginger extract is provided to prevent and treat neurodegenerative diseases. CONSTITUTION: A composition for preventing and treating neurodegenerative diseases contains a standardized fraction of crude ginger extract as an active ingredient. The ginger is a root stem of Zingiberaceae. The crude extract is obtained by heating, sonication, or reflux. The suspension is prepared by adding water such as distilled water and purified water to the crude extract. The standardized fraction contains 1.0-10%(w/w) of 6-gingerol.

Abstract translation: 目的：提供含有粗姜提取物标准化部分的药物组合物和营养食品，用于预防和治疗神经变性疾病。 构成：用于预防和治疗神经变性疾病的组合物含有作为活性成分的粗姜提取物的标准化分数。 姜是姜科的根茎。 粗提物通过加热，超声处理或回流获得。 通过向粗提物中加入蒸馏水和净化水等水制备悬浮液。 标准化级分含有1.0-10％（w / w）的6-姜醇。

公开(公告)号：KR1020100100020A

公开(公告)日：2010-09-15

申请号：KR1020090018670

申请日：2009-03-05

Applicant: 원광대학교산학협력단

Inventor： 박현 ,  김옥진 ,  김윤철 ,  김성연

IPC: A61K36/22 ,  A61P1/04 ,  A23L1/30 ,  A61P35/00

Abstract: PURPOSE: A composition with antibacterial activity against helicobacter bacteria is provided to ensure excellent antibacterial activity and to prevent and treat diseases caused by helicobacter bacteria infection. CONSTITUTION: A pharmaceutical composition for preventing and treating helicobacter bacteria infection contains galla rhois extract as an active ingredient. The galla rhois extract is isolated using water, low alcohol of C1-C4 or mixture solvent thereof. A health food for preventing and treating gastritis, gastric ulcer, and gastric cancer caused by helicobacter bacteria infection contains galla rhois extract as an active ingredient. The health food is used in the form of powder, granule, tablet, capsule or beverage.

Abstract translation: 目的：提供具有抗幽门螺杆菌抗菌活性的组合物，以确保优良的抗菌活性，并预防和治疗由幽门螺杆菌感染引起的疾病。 构成：用于预防和治疗幽门螺杆菌感染的药物组合物含有胆红素提取物作为活性成分。 使用水，C1-C4的低级醇或其混合溶剂分离胆汁提取物。 一种用于预防和治疗由幽门螺杆菌感染引起的胃炎，胃溃疡和胃癌的保健食品含有胆红素提取物作为活性成分。 保健食品以粉末，颗粒，片剂，胶囊或饮料的形式使用。

公开(公告)号：KR1020100100019A

公开(公告)日：2010-09-15

申请号：KR1020090018669

申请日：2009-03-05

Applicant: 원광대학교산학협력단

Inventor： 박현 ,  김옥진 ,  김윤철 ,  이현아 ,  홍선화

IPC: A61K36/22 ,  A61P31/04 ,  A23K1/14 ,  A61P1/04

Abstract: PURPOSE: A composition with antibacterial activity, containing galla rhois extract is provided to ensure excellent antibacterial effect and to use as veterinary medicinary medicinal composition and feed additive. CONSTITUTION: A veterinary medicinal composition for preventing and treating helicobacter bacterial infection contains 0.1-50 weight% of galla rhois extract as an active ingredient. The galla rhois extract is isolated using water, low alcohol of C1-C4, or mixture solvent thereof. The animal of helicobacter infection is mammals, fishes, and poultry. The helicobacter bacteria are Helicobacter pylori, Helicobacter heilmannii, Helicobacter felis, Helicobacter mustelae, Helicobacter fenelliae, Helicobacter rappini, Helicobacter hepaticus, Helicobacter bilis, or Helicobacter pullorum. An animal feed additive for preventing and treating helicobacter bacteria infection contains galla rhois extract as an active ingredient.

Abstract translation: 目的：提供含有罗勒精提取物的具有抗菌活性的组合物，以确保优异的抗菌效果，并用作兽药医药组合物和饲料添加剂。 构成：用于预防和治疗幽门螺杆菌细菌感染的兽用药物组合物含有0.1-50重量％的罗勒提取物作为活性成分。 使用水，C1-C4的低级醇或其混合溶剂分离胆汁提取物。 幽门螺杆菌感染的动物是哺乳动物，鱼类和家禽。 幽门螺杆菌是幽门螺杆菌，赫氏杆菌，幽门螺杆菌，龙胆螺杆菌，龙胆螺杆菌，拉米尼杆菌，肝杆菌，幽门螺杆菌或幽门螺杆菌。 用于预防和治疗螺杆菌感染的动物饲料添加剂含有胆红素提取物作为活性成分。

公开(公告)号：KR1020100039033A

公开(公告)日：2010-04-15

申请号：KR1020080098235

申请日：2008-10-07

Applicant: 원광대학교산학협력단

Inventor： 손동환 ,  김윤철 ,  박은전 ,  최후균

IPC: A61K9/10 ,  A61K36/536

Abstract: PURPOSE: A rapid effective solid dispersion of Salvia miltiorrhiza extract and oral formulation containing the same are provided to improve solubility, stability and release rate. CONSTITUTION: A rapid effective solid dispersion contains Salvia miltiorrhiza extract and polyxyethylenepolyoxypropylene-polyoxyethylene copolymer. Salvia miltiorrhiza extract contains 40-90 weight% of Cryptotanshinone, tanshinone I or tanshinone IIA. The Salvia miltiorrhiza extract is isolated using water, methanole, ethanol and butanol. A rapid effective oral formulation comprises a solid dispersion of the Salvia miltiorrhiza extract and polyoxyethylene-polyoxypropylene-polyoxyethylene copolymer, and pharmaceutically acceptable oral carrier or excipient.

Abstract translation: 目的：提供丹参提取物和含有其的口服制剂的快速有效固体分散体，以提高溶解性，稳定性和释放速率。 构成：快速有效的固体分散体含有丹参提取物和聚亚乙基聚氧丙烯 - 聚氧乙烯共聚物。 丹参提取物含有40-90重量％的加仑丹参酮，丹参酮I或丹参酮IIA。 使用水，甲醇，乙醇和丁醇分离丹参提取物。 快速有效的口服制剂包括丹参提取物和聚氧乙烯 - 聚氧丙烯 - 聚氧乙烯共聚物的固体分散体和药学上可接受的口服载体或赋形剂。

公开(公告)号：KR100946466B1

公开(公告)日：2010-03-10

申请号：KR1020070007511

申请日：2007-01-24

Applicant: 원광대학교산학협력단

Inventor： 박현 ,  김윤철 ,  강경화 ,  김혜숙 ,  와타야유우스케 ,  카마타마사키

IPC: C07D493/08 ,  A61K31/357

Abstract: 본 발명은 톡소포자충 억제 활성을 갖는 신규 화합물 및 이를 포함하는 조성물에 관한 것으로, 상세하게는 엔도페록시드(endoperoxide) 구조를 갖는 1,5-디페닐-8-메틸-6,7-디옥사-바이시클로[3.2.2]노난 베타체(1,5-diphenyl-8-methyl-6,7-dioxa-bicyclo[3.2.2]nonane)화합물은 콕시디움, 즉 톡소포자충의 증식에 뛰어난 억제 효과를 나타내므로 톡소플라즈마증(Toxoplasmosis)의 예방 및 치료에 유용하게 이용될 수 있다.
1,5-디페닐-8-메틸-6,7-디옥사-바이시클로[3.2.2]노난 베타체, 엔도페록시드, 톡소포자충, 톡소플라즈마증

公开(公告)号：KR1020090059231A

公开(公告)日：2009-06-11

申请号：KR1020070125969

申请日：2007-12-06

Applicant: 원광대학교산학협력단

Inventor： 손동환 ,  김윤철 ,  박은전

IPC: A61K31/35 ,  A61K31/352 ,  A61P1/16

Abstract: A composition for preventing and treating liver disease is provided to ensure the effects of DNA fragmentation suppression, caspase-3 and caspase-8 activity inhibition, poly(ADP-ribose)polymerase inhibition and JNK phosphorylation inhibition. A composition for treating and preventing liver disease comprises an oroxylin A of the chemical formula A as an active ingredient. The oroxylin A suppresses the liver cell damage by bilestagnation. The liver disease is selected from autoimmunity liver disease, drug attractancy liver disease, adrenoleukodystrophy, infection liver disease, congenital metabolic liver disease, bile congestion, acute hepatitis, permanent exposure, cirrhosis, steatosis or liver cancer. The composition is contained in a ratio of 0.1-50 weight% based on total weight. A health functional food containing the oroxylin A for preventing liver disease and improving cure thereof is used in a form of powder, granule, tablet, capsule and beverage.

Abstract translation: 提供预防和治疗肝病的组合物，以确保DNA断裂抑制，半胱天冬酶-3和半胱天冬酶-8活性抑制，聚（ADP-核糖）聚合酶抑制和JNK磷酸化抑制的作用。 用于治疗和预防肝病的组合物包含化学式A的奥昔克霉素A作为活性成分。 奥昔克霉素A通过双向抑制来抑制肝细胞损伤。 肝病选自自身免疫性肝病，吸毒性肝病，肾上腺脑白质营养不良，感染性肝病，先天性代谢性肝病，胆汁充血，急性肝炎，永久性暴露，肝硬化，脂肪变性或肝癌。 所述组合物的含量占总重量的0.1-50重量％。 以粉末，颗粒，片剂，胶囊和饮料的形式使用含有用于预防肝脏疾病和改善其固化的奥昔克霉素A的保健功能食品。

公开(公告)号：KR100830202B1

公开(公告)日：2008-05-19

申请号：KR1020070136180

申请日：2007-12-24

Applicant: 원광대학교산학협력단

Inventor： 김윤철 ,  박현 ,  강경화

IPC: A61K31/351 ,  A61K36/63 ,  A61P33/00

Abstract: A composition comprising fraxidin isolated from Fraxinus rhynchophylla is provided to show inhibitory effect on toxoplasma, thereby being usefully used as a pharmaceutical composition for preventing and treating toxoplasmosis. A pharmaceutical composition for preventing and treating toxoplasmosis comprises 0.1-50 wt.% of fraxidin isolated from Fraxini Cortex of Fraxinus rhynchophylla and represented by a formula(1). An antiprotozoan supplement agent for preventing and treating toxoplasma comprises the fraxidin.

Abstract translation: 提供了包含从弗氏毒素（Rhinchophylla）分离的弗氏鼠杆菌的组合物，以显示对弓形体的抑制作用，从而有效地用作预防和治疗弓形虫病的药物组合物。 用于预防和治疗弓形体病的药物组合物包含0.1-50％（重量）的由弗氏rh from（Fraxinus rhynchophylla）的Fraxini Cortex分离并由式（1）表示的菌丝孢菌素。 用于预防和治疗弓形体的抗原生动物补充剂包括弗地克星。

公开(公告)号：KR100830186B1

公开(公告)日：2008-05-16

申请号：KR1020060048798

申请日：2006-05-30

Applicant: 원광대학교산학협력단

Inventor： 손동환 ,  김윤철 ,  박은전 ,  조우철

IPC: A61K36/539 ,  A61P1/16

Abstract: 본 발명은 황금 (
Scutellaria

baicalensis
GEORGI) 정제 추출물의 제조방법 및 상기 정제 추출물을 유효성분으로 함유하는 조성물에 관한 것이다. 보다 구체적으로, 3단계의 간단한 공정으로 구성된 제조방법으로 제조된 본 발명의 황금 표준화 시료용 정제 추출물은 황금의 주요 생리활성 성분인 바이칼레인 (baicalein), 우고닌 (wogonin) 및 오록실린 A (oroxylin A)를 고농도로 함유하고 있으며, 탁월한 간 보호 및 담즙정체에 의한 자가 사멸로부터의 간 보호 효능을 가지므로, 본 발명의 제조방법에 의해 제조된 황금 표준화시료용 정제 추출물 또는 이를 함유하는 조성물은 간보호 및 담즙성 간경변증 예방 및 치료용 조성물로 사용될 수 있다.
황금, 정제 추출물, 간세포, 담즙정체, 자가사멸, 간 보호, 담즙성 간경변증

公开(公告)号：KR100827938B1

公开(公告)日：2008-05-08

申请号：KR1020060046957

申请日：2006-05-25

Applicant: 원광대학교산학협력단

Inventor： 손동환 ,  김윤철 ,  박은전

IPC: A61K36/537 ,  A61P1/16

Abstract: 본 발명은 단삼 (
Salvia
miltiorrhiza
BUNGE) 정제 추출물의 제조방법 및 상기 정제 추출물을 유효성분으로 함유하는 조성물에 관한 것이다. 보다 구체적으로, 3단계의 간단한 공정으로 구성된 제조방법으로 제조된 본 발명의 단삼 표준화 시료용 정제 추출물은 단삼의 주요 생리활성 성분인 크립토탄시논 (cryptotanshinone), 탄시논 I (tanshinone I) 및 탄시논 ⅡA (tanshinone ⅡA)를 고농도로 함유하고 있으며, 기존 알려진 단삼 추출물과 비교하여 탁월한 간 보호, 항섬유화 효능 및 담즙정체에 의한 자가 사멸로부터의 간 보호 효능을 가지므로, 본 발명의 제조방법에 의해 제조된 단삼 표준화시료용 정제 추출물 또는 이를 함유하는 조성물은 간 보호제, 간섬유화 또는 간경화증 예방 및 치료용 조성물로 사용될 수 있다.
단삼, 정제 추출물, 간세포, 담즙정체, 자가사멸, 간 보호, 간섬유화, 간경화증

公开(公告)号：KR1020070113561A

公开(公告)日：2007-11-29

申请号：KR1020060046957

申请日：2006-05-25

Applicant: 원광대학교산학협력단

Inventor： 손동환 ,  김윤철 ,  박은전

IPC: A61K36/537 ,  A61P1/16

CPC classification number: A61K36/537 ,  A61K2236/331 ,  Y10S514/838 ,  Y10S514/893

Abstract: A method for preparing a purified extract of Salvia miltiorrhiza is provided to obtain the extract which contains cryptotanshinone, tanshinone I and tanshinone IIA at high concentration and show excellent liver protecting effect, antifibrotic effect, and liver cell apoptosis inhibitory effect, thereby being usefully used as a pharmaceutical composition and a health supplement food for treating and preventing hepatic fibrosis or liver cirrhosis. A method for preparing a purified extract of Salvia miltiorrhiza comprises the steps of: (a) preparing a crude extract of dried Salvia miltiorrhiza by extraction with a lower alcohol solvent, filtration, concentration under reduced pressure and drying; (b) suspending the crude extract in water and then filtering the suspension to obtain a water-insoluble residue; (c) after adding lower alcohol to the residue, agitating, dissolving and filtering it to obtain filtrate; and (d) removing solvent remaining from the filtrate. A pharmaceutical composition comprises the purified extract of Salvia miltiorrhiza as an effective ingredient, and a pharmaceutically acceptable carrier or an excipient.

Abstract translation: 提供了一种制备丹参提纯物的方法，以高浓度获得含有隐丹参酮，丹参酮I和丹参酮IIA的提取物，具有优异的肝保护作用，抗纤维化作用和肝细胞凋亡抑制作用，有效地用作 用于治疗和预防肝纤维化或肝硬化的药物组合物和保健补充食品。 制备丹参净化提取物的方法包括以下步骤：（a）通过用低级醇溶剂萃取，过滤，减压浓缩并干燥，制备干燥的丹参粗提物; （b）将粗提物悬浮于水中，然后过滤悬浮液，得到水不溶性残渣; （c）向残渣中加入低级醇后，搅拌，溶解并过滤，得到滤液; 和（d）从滤液中除去残留的溶剂。 药物组合物包含丹参的纯化提取物作为有效成分，以及药学上可接受的载体或赋形剂。